Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results this Monday after market hours. Here’s what to expect. Exact Sciences beat analysts’ revenue ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations , with sales up 16% year on year to $811.1 million. The company’s ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Your website’s domain name is the digital real estate your entire brand is built upon. Great domains are easy to remember, type in and share. With thousands of domain extensions and more than 332 ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

Earnings Call Insights: Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Kevin Conroy, Chairman and CEO, highlighted Exact Sciences' progress in 2024, including delivering over 4.6 million test ...

Welcome to our weekly Search Engine Land series, Everything you need to know about Google Ads in less than 3 minutes. Every Wednesday, I’m highlighting a different Google Ads feature, and what you ...